Overview

Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

Status:
Completed
Trial end date:
2020-08-10
Target enrollment:
Participant gender:
Summary
This trial will evaluate safety and efficacy of letetresgene autoleucel (GSK3377794) in participants with metastatic NSCLC.
Phase:
Phase 1
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Cyclophosphamide
Fludarabine